Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Giant Cell Arteritis HELP
Based on 2,512 articles published since 2009
||||

These are the 2512 published articles about Giant Cell Arteritis that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis. 2019

Turesson, C / Börjesson, O / Larsson, K / Mohammad, A J / Knight, A. ·a Rheumatology, Department of Clinical Sciences , Malmö, Lund University , Malmö , Sweden. · b Department of Rheumatology , Skåne University Hospital , Malmö , Sweden. · c Department of Rheumatology , Karolinska University Hospital , Stockholm , Sweden. · d Department of Rheumatology , Sahlgrenska University Hospital , Gothenburg , Sweden. · e Rheumatology, Department of Clinical Sciences, Lund , Lund University , Lund , Sweden. · f Department of Rheumatology , Skåne University Hospital , Lund , Sweden. · g Rheumatology, Department of Medical Sciences , Uppsala University , Uppsala , Sweden. ·Scand J Rheumatol · Pubmed #30838907.

ABSTRACT:

2 Guideline Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). 2016

Bienvenu, B / Ly, K H / Lambert, M / Agard, C / André, M / Benhamou, Y / Bonnotte, B / de Boysson, H / Espitia, O / Fau, G / Fauchais, A-L / Galateau-Sallé, F / Haroche, J / Héron, E / Lapébie, F-X / Liozon, E / Luong Nguyen, L B / Magnant, J / Manrique, A / Matt, M / de Menthon, M / Mouthon, L / Puéchal, X / Pugnet, G / Quemeneur, T / Régent, A / Saadoun, D / Samson, M / Sène, D / Smets, P / Yelnik, C / Sailler, L / Mahr, A / Anonymous110857. ·Service de médecine interne, CHU de Caen, Normandie university, 14003 Caen, France. · Service de médecine interne, hôpital Dupuytren, CHU de Limoges, université de Limoges, 87000 Limoges, France. · Service de médecine interne, hôpital Huriez, CHRU de Lille, université Nord-de-France, 59037 Lille, France. · Service de médecine interne, hôpital Hôtel-Dieu, CHU de Nantes, université de Nantes, 44093 Nantes, France. · Service de médecine interne, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, université d'Auvergne, 63001 Clermont-Ferrand, France. · Département de médecine interne, CHU de Rouen, université de Rouen, 76031 Rouen, France. · Service de médecine interne et immunologie clinique, CHU François-Mitterrand, université de Bourgogne Franche-Comté, 21079 Dijon, France. · Service de radiologie centrale, hôpital Hôtel-Dieu, CHU de Nantes, université de Nantes, 44093 Nantes, France. · Département d'anatomie pathologique, CHU de Caen, université de Normandie, 14003 Caen, France. · Service de médecine interne 2, CHU Pitié-Salpêtrière, université Paris 6, 75013 Paris, France. · Service de médecine interne, centre hospitalier national d'ophtalmologie des Quinze-Vingts, université Paris 6, 75012 Paris, France. · Unité de médecine interne-maladies systémiques, département de médecine interne, hôpital Saint-Louis, CHU Saint-Louis, université Paris Diderot, 1, avenue Claude-Vellefaux, 75010 Paris, France. · Service de médecine interne, CHU de Tours, université François-Rabelais, 37044 Tours, France. · Service de médecine nucléaire, CHU de Caen, Normandie université, 14003 Caen, France. · Service de médecine interne, CHU de Cochin, université Paris 5-René Descartes, 75014 Paris, France. · Service de médecine interne, hôpital Purpan, CHU de Toulouse, université de Toulouse, 31059 Toulouse, France. · Service de médecine interne et néphrologie, hôpital de Valenciennes, 59300 Valenciennes, France. · Département de médecine interne et immunologie clinique, CHU Pitié-Salpêtrière, université Paris 6, 75013 Paris, France. · Département de médecine interne, CHU Lariboisière, université Paris Diderot, 75010 Paris, France. · Unité de médecine interne-maladies systémiques, département de médecine interne, hôpital Saint-Louis, CHU Saint-Louis, université Paris Diderot, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: alfred.mahr@aphp.fr. ·Rev Med Interne · Pubmed #26833145.

ABSTRACT: PURPOSE: Management of giant cell arteritis (GCA, Horton's disease) involves many uncertainties. This work was undertaken to establish French recommendations for GCA management. METHODS: Recommendations were developed by a multidisciplinary panel of 33 physicians, members of the French Study Group for Large Vessel Vasculitis (Groupe d'étude français des artérites des gros vaisseaux [GEFA]). The topics to be addressed, selected from proposals by group members, were assigned to subgroups to summarize the available literature and draft recommendations. Following an iterative consensus-seeking process that yielded consensus recommendations, the degree of agreement among panel members was evaluated with a 5-point Likert scale. A recommendation was approved when ≥ 80% of the voters agreed or strongly agreed. RESULTS: The 15 retained topics resulted in 31 consensus recommendations focusing on GCA nomenclature and classification, the role of temporal artery biopsy and medical imaging in the diagnosis, indications and search modalities for involvement of the aorta and its branches, the glucocorticoid regimen to prescribe, treatment of complicated GCA, indications for use of immunosuppressants or targeted biologic therapies, adjunctive treatment measures, and management of relapse and recurrence. CONCLUSIONS: The recommendations, which will be updated regularly, are intended to guide and harmonize the standards of GCA management.

3 Guideline 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. 2015

Dejaco, Christian / Singh, Yogesh P / Perel, Pablo / Hutchings, Andrew / Camellino, Dario / Mackie, Sarah / Abril, Andy / Bachta, Artur / Balint, Peter / Barraclough, Kevin / Bianconi, Lina / Buttgereit, Frank / Carsons, Steven / Ching, Daniel / Cid, Maria / Cimmino, Marco / Diamantopoulos, Andreas / Docken, William / Duftner, Christina / Fashanu, Billy / Gilbert, Kate / Hildreth, Pamela / Hollywood, Jane / Jayne, David / Lima, Manuella / Maharaj, Ajesh / Mallen, Christian / Martinez-Taboada, Victor / Maz, Mehrdad / Merry, Steven / Miller, Jean / Mori, Shunsuke / Neill, Lorna / Nordborg, Elisabeth / Nott, Jennifer / Padbury, Hannah / Pease, Colin / Salvarani, Carlo / Schirmer, Michael / Schmidt, Wolfgang / Spiera, Robert / Tronnier, David / Wagner, Alexandre / Whitlock, Madeline / Matteson, Eric L / Dasgupta, Bhaskar / Anonymous2330842 / Anonymous2340842. ·Department of Rheumatology, Medical University Graz, Graz, Austria Department of Rheumatology, Southend University Hospital, Southend, UK. · Department of Rheumatology, Southend University Hospital, Southend, UK. · Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. · Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK. · Department of Internal Medicine, Research Laboratory and Academic Division of Clinical Rheumatology, University of Genova, Genoa, Italy. · University of Leeds, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK. · Department of Rheumatology, Mayo Clinic, Jacksonville, Florida, USA. · Department of Internal Medicine and Rheumatology, Military Institute of Medicine, Warsaw, Poland. · 3rd Rheumatology Department, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary. · Hoyland House General Practice, Painswick, UK. · General Practice, Bibbiano, Italy. · Department of Rheumatology, Charitè University Medicine, Berlin, Germany. · Division of Rheumatology, Allergy and Immunology, Winthrop-University Hospital Campus, Stony Brook University School of Medicine, Mineola, New York, USA. · Department of Rheumatology, Timaru Hospital, Timaru, New Zealand. · Department of Systemic Autoimmune Diseases, University of Barcelona, Hospital Clinic, Barcelona, Spain. · Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway. · Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA. · Department of Internal Medicine-Clinic VI, Medical University of Innsbruck, Innsbruck, Austria. · Patient Representative from PMRGCAuk, UK. · Department of Medicine, University of Cambridge, Cambridge, UK. · Department of Rheumatology, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil. · Department of Internal Medicine, University of Kwa Zulu Natal, Prince Mshiyeni Memorial Hospital, Nelson R Mandela School of Medicine, Durban, South Africa. · Arthritis Research UK Primary Care Centre, Keele University, Keele, UK. · Facultad de Medicina, Servicio de Reumatología, Universidad de Cantabria, Hospital Universitario Marqués de Valdecilla, Santander, Spain. · Department of Medicine, Division of Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center Kansas City, Kansas, USA. · Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA. · Department of Rheumatology, NHO Kumamoto Saishunsou National Hospital, Clinical Research Center for Rheumatic Diseases, Kohshi, Kumamoto, Japan. · Department of Rheumatology, Sahlgren University Hospital, Göteborg, Sweden. · Department of Internal Medicine, Division of Rheumatology, Azienda Ospedaliera-IRCCS di Reggio Emilia, Reggio Emilia, Italy. · Immanuel Krankenhaus Berlin: Medical Center for Rheumatology Berlin-Buch Berlin, Berlin, Germany. · Department of Medicine, Hospital for Special Surgery, New York, New York, USA. · Patient Representative from the USA. · Department of Internal Medicine, Universidade Federal de São Paulo, São Paulo, Brazil. · Department of Health Sciences Research, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. ·Ann Rheum Dis · Pubmed #26359488.

ABSTRACT: Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the recommendations are based on the quality of evidence, the balance between desirable and undesirable effects, patients' and clinicians' values and preferences, and resource use. Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow-up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid (GC) doses and subsequent tapering regimens, use of intramuscular GCs and disease modifying anti-rheumatic drugs (DMARDs), as well as the roles of non-steroidal anti-rheumatic drugs and non-pharmacological interventions. These recommendations will inform primary, secondary and tertiary care physicians about an international consensus on the management of PMR. These recommendations should serve to inform clinicians about best practices in the care of patients with PMR.

4 Guideline 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. 2015

Dejaco, Christian / Singh, Yogesh P / Perel, Pablo / Hutchings, Andrew / Camellino, Dario / Mackie, Sarah / Abril, Andy / Bachta, Artur / Balint, Peter / Barraclough, Kevin / Bianconi, Lina / Buttgereit, Frank / Carsons, Steven / Ching, Daniel / Cid, Maria / Cimmino, Marco / Diamantopoulos, Andreas / Docken, William / Duftner, Christina / Fashanu, Billy / Gilbert, Kate / Hildreth, Pamela / Hollywood, Jane / Jayne, David / Lima, Manuella / Maharaj, Ajesh / Mallen, Christian / Martinez-Taboada, Victor / Maz, Mehrdad / Merry, Steven / Miller, Jean / Mori, Shunsuke / Neill, Lorna / Nordborg, Elisabeth / Nott, Jennifer / Padbury, Hannah / Pease, Colin / Salvarani, Carlo / Schirmer, Michael / Schmidt, Wolfgang / Spiera, Robert / Tronnier, David / Wagner, Alexandre / Whitlock, Madeline / Matteson, Eric L / Dasgupta, Bhaskar / Anonymous560842 / Anonymous570842. ·Medical University Graz, Department of Rheumatology, Graz, Austria, and Southend University Hospital, Department of Rheumatology, Essex, UK. · Southend University Hospital, Department of Rheumatology, Essex, UK. · London School of Hygiene and Tropical Medicine, Epidemiology and Population Health Faculty, London, UK. · London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy, London, UK. · University of Genoa, Department of Internal Medicine, Research Laboratory and Academic Division of Clinical Rheumatology, Genoa, Italy. · University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK. · Mayo Clinic, Department of Rheumatology, Jacksonville, Florida. · Military Institute of Medicine, Department of Internal Medicine and Rheumatology, Warsaw, Poland. · National Institute of Rheumatology and Physiotherapy, 3rd Rheumatology Department, Budapest, Hungary. · Hoyland House, Painswick, UK. · Bibbiano, Italy. · Charité University Medicine, Department of Rheumatology, Berlin, Germany. · Stony Brook University School of Medicine, Division of Rheumatology, Allergy and Immunology, Winthrop-University Hospital Campus, Mineola, New York. · Timaru Hospital, Department of Rheumatology, Timaru, New Zealand. · University of Barcelona Hospital Clinic, Department of Systemic Autoimmune Diseases, Barcelona, Spain. · Hospital of Southern Norway Trust, Department of Rheumatology, Kristiansand, Norway. · Brigham and Women's Hospital, Division of Rheumatology, Boston, Massachusetts. · Medical University of Innsbruck, Department of Internal Medicine-Clinic VI, Innsbruck, Austria. · patient representatives from Polymyalgia Rheumatica and Giant Cell Arteritis UK, London, UK. · University of Cambridge, Department of Medicine, Cambridge, UK. · Hospital Universitário Pedro Ernesto, Department of Rheumatology, Rio de Janeiro, Brazil. · University of Kwa Zulu Natal, Prince Mshiyeni Memorial Hospital, Nelson R. Mandela School of Medicine, Department of Internal Medicine, Durban, South Africa. · Keele University, Arthritis Research UK Primary Care Centre, Keele, UK. · Universidad de Cantabria, Hospital Universitario Marqués de Valdecilla, Facultad de Medicina, Servicio de Reumatología, Santander, Spain. · University of Kansas Medical Center, Department of Medicine, Division of Allergy, Clinical Immunology, and Rheumatology, Kansas City. · Mayo Clinic, Department of Family Medicine, Rochester, Minnesota. · NHO Kumamoto Saishunsou National Hospital, Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, Kohshi, Kumamoto, Japan. · Sahlgren University Hospital, Department of Rheumatology, Göteborg, Sweden. · Azienda Ospedaliera-IRCCS di Reggio Emilia, Department of Internal Medicine, Division of Rheumatology, Reggio Emilia, Italy. · Immanuel Krankenhaus Berlin and Medical Center for Rheumatology Berlin-Buch, Berlin, Germany. · Hospital for Special Surgery, Department of Medicine, New York, New York. · patient representative from the Mayo Clinic, Rochester, Minnesota. · Universidade Federal de São Paulo, Department of Internal Medicine, São Paulo, Brazil. · Mayo Clinic College of Medicine, Department of Health Sciences Research, Division of Rheumatology, Rochester, Minnesota. ·Arthritis Rheumatol · Pubmed #26352874.

ABSTRACT: Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the recommendations are based on the quality of evidence, the balance between desirable and undesirable effects, patients' and clinicians' values and preferences, and resource use. Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow-up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid (GC) doses and subsequent tapering regimens, use of intramuscular GCs and disease modifying anti-rheumatic drugs (DMARDs), as well as the roles of non-steroidal anti-rheumatic drugs and non-pharmacological interventions. These recommendations will inform primary, secondary and tertiary care physicians about an international consensus on the management of PMR. These recommendations should serve to inform clinicians about best practices in the care of patients with PMR.

5 Guideline Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. 2015

Stone, James R / Bruneval, Patrick / Angelini, Annalisa / Bartoloni, Giovanni / Basso, Cristina / Batoroeva, Lubov / Buja, L Maximilian / Butany, Jagdish / d'Amati, Giulia / Fallon, John T / Gittenberger-de Groot, Adriana C / Gouveia, Rosa H / Halushka, Marc K / Kelly, Karen L / Kholova, Ivana / Leone, Ornella / Litovsky, Silvio H / Maleszewski, Joseph J / Miller, Dylan V / Mitchell, Richard N / Preston, Stephen D / Pucci, Angela / Radio, Stanley J / Rodriguez, E Rene / Sheppard, Mary N / Suvarna, S Kim / Tan, Carmela D / Thiene, Gaetano / van der Wal, Allard C / Veinot, John P. ·Massachusetts General Hospital, Boston, MA, USA. Electronic address: jrstone@partners.org. · University Paris-Descartes, France. Electronic address: patrick.bruneval@egp.aphp.fr. · University of Padua Medical School, Padua, Italy. · University of Catania, Catania, Italy. · Russian Academy of Medical Sciences, Irkutsk, Russia. · University of Texas Health Science Center at Houston, Houston, TX, USA. · Toronto General Hospital, Toronto, Canada. · Sapienza, University of Rome, Rome, Italy. · New York Medical College, Valhalla, NY, USA. · Leiden University, Leiden, the Netherlands. · Hospital Santa Cruz, Carnaxide, Portugal. · Johns Hopkins University, Baltimore, MD, USA. · East Carolina University, Greenville, NC, USA. · Fimlab Laboratories, Tampere, Finland. · Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. · University of Alabama at Birmingham, Birmingham AL, USA. · Mayo Clinic, Rochester, MN, USA. · University of Utah, UT, USA. · Brigham and Women's Hospital, Boston, MA, USA. · Papworth Hospital, Cambridgeshire, UK. · Pisa University Hospital, Pisa, Italy. · University of Nebraska, NE, USA. · Cleveland Clinic, Cleveland, OH, USA. · St George Medical School, University of London, London, UK. · Sheffield Teaching Hospitals, Sheffield, UK. · University of Amsterdam, Amsterdam, the Netherlands. · University of Ottawa, Ottawa, Ontario, Canada. ·Cardiovasc Pathol · Pubmed #26051917.

ABSTRACT: Inflammatory diseases of the aorta include routine atherosclerosis, aortitis, periaortitis, and atherosclerosis with excessive inflammatory responses, such as inflammatory atherosclerotic aneurysms. The nomenclature and histologic features of these disorders are reviewed and discussed. In addition, diagnostic criteria are provided to distinguish between these disorders in surgical pathology specimens. An initial classification scheme is provided for aortitis and periaortitis based on the pattern of the inflammatory infiltrate: granulomatous/giant cell pattern, lymphoplasmacytic pattern, mixed inflammatory pattern, and the suppurative pattern. These inflammatory patterns are discussed in relation to specific systemic diseases including giant cell arteritis, Takayasu arteritis, granulomatosis with polyangiitis (Wegener's), rheumatoid arthritis, sarcoidosis, ankylosing spondylitis, Cogan syndrome, Behçet's disease, relapsing polychondritis, syphilitic aortitis, and bacterial and fungal infections.

6 Guideline Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. 2012

Pipitone, Nicolò / Olivieri, Ignazio / Salvarani, Carlo / Anonymous2050727. ·Rheumatology Department, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. pipitone.nicolo@asmn.re.it ·Clin Exp Rheumatol · Pubmed #22640657.

ABSTRACT: OBJECTIVES: To provide recommendations on behalf of the Italian Society for Rheumatology for the off-label use of biologic agents in the treatment of large-vessel vasculitis. METHODS: A panel of experts performed a literature search and selected the evidence relevant to the topic. The following five large-vessel vasculitides were considered: giant cell arteritis, Takayasu arteritis, primary angiitis of the central nervous system, Cogan's syndrome, and Adamantiades-Behçet's disease. RESULTS: A consensus was achieved regarding the indication of biologic agents for the treatment of large-vessel vasculitis. Levels of evidence were assigned to the papers retrieved, and the strength of the recommendations was graded according to the levels of evidence. CONCLUSIONS: These recommendations may be used for guidance in deciding which patients with large-vessel vasculitis should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.

7 Guideline Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. 2011

Anonymous1001397. · ·Circ J · Pubmed #21263196.

ABSTRACT: -- No abstract --

8 Guideline Concise guidance: diagnosis and management of giant cell arteritis. 2010

Dasgupta, Bhaskar / Anonymous2631223. ·Essex University Southend University Hospital, Westcliff-on-Sea, Essex. bhaskar.dasgupta@southend.nhs.uk ·Clin Med (Lond) · Pubmed #20849016.

ABSTRACT: Giant cell arteritis (GCA) or temporal arteritis (TA) with polymyalgia rheumatica (PMR) is among the most common reasons for long-term steroid prescription. GCA is a critically ischaemic disease, the most common form of vasculitis and should be treated as a medical emergency. Visual loss occurs in up to a fifth of patients, which may be preventable by prompt recognition and treatment. The British Society for Rheumatology (BSR) and the British Health Professionals in Rheumatology (BHPR) have recently published guidelines on the management of PMR. The purpose of this concise guidance is to draw attention to the full guidelines to encourage the prompt diagnosis and urgent management of GCA, with emphasis on the prevention of visual loss. They provide a framework for disease assessment, immediate treatment and referral to specialist care for management and monitoring of disease activity, complications and relapse.

9 Guideline [Classification and therapy of vasculitis according to recommendations of the European League Against Rheumatism (EULAR)]. 2010

Holle, J U / Bley, T / Gross, W L. ·Klinik für Rheumatologie und Klinische Immunologie, Klinikum Bad Bramstedt, Oskar-Alexander-Str. 26, 24576, Bad Bramstedt, Deutschland. holle@klinikumbb.de ·Radiologe · Pubmed #20717646.

ABSTRACT: Vasculitis is still being classified according the criteria of the American College of Rheumatology and the Chapel Hill Consensus Conference Definitions. Diagnostic criteria are currently being established. The classification criteria are based on the size of the inflamed blood vessel (e.g. large vessel vasculitis with inflammation of the aorta and its branches), clinical symptoms and findings (such as cephalalgia in giant cell arteritis) and histological findings. In recent years a definition of disease stages and activity has been established and a number of controlled trials have been carried out in order to provide evidence-based stage and activity adapted therapy regimens. Recommendations for the management of vasculitis have been published in 2009 by EULAR (European League Against Rheumatism). This article gives a review of the classification of vasculitis and summarizes the current European guidelines on management.

10 Guideline [Dutch College of General Practitioner's practice guideline on polymyalgia rheumatica and temporal arteritis]. 2010

Eizenga, Wietze H / Hakvoort, Louwe / Dubbeld, Peter / Geijer, Roeland M M / Goudswaard, A N Lex / Anonymous3290661. ·Nederlands Huisartsen Genootschap, afd. Richtlijnontwikkeling en Wetenschap, Utrecht, The Netherlands. W.Eizenga@nhg.org ·Ned Tijdschr Geneeskd · Pubmed #20482924.

ABSTRACT: The practice guideline for general practitioners (GPs) on polymyalgia rheumatica and temporal arteritis was published in February 2010 by the Dutch College of General Practitioners. This guideline provides GPs with recommendations for the diagnosis and treatment of polymyalgia rheumatica. After other disorders have been excluded, the diagnosis of 'polymyalgia rheumatica' is made in patients over the age of 50 who have bilateral pain in the neck and shoulder girdle and/or hip girdle that has lasted for longer than 4 weeks, morning stiffness that lasts longer than 60 minutes and an ESR > 40 mm in the first hour. After the diagnosis is made treatment with prednisone or prednisolone 15 mg per day is started. This dosage is diminished very gradually according to a uniform treatment schedule during a period of 3 months, thereafter depending on the clinical course. The practice guideline pays attention to the diagnosis and management of temporal arteritis only when it occurs concurrently with polymyalgia rheumatica.

11 Editorial [New concepts in giant cell arteritis]. 2019

Samson, Maxime / Bonnotte, Bernard. ·CHU Dijon Bourgogne, hôpital François-Mitterrand, université Bourgogne-Franche Comté, service de médecine interne et immunologie clinique, Inserm, EFS BFC, UMR1098, 2, boulevard Mal-de-Lattre-de-Tassigny, 21000 Dijon, France. Electronic address: maxime.samson@chu-dijon.fr. · CHU Dijon Bourgogne, hôpital François-Mitterrand, université Bourgogne-Franche Comté, service de médecine interne et immunologie clinique, Inserm, EFS BFC, UMR1098, 2, boulevard Mal-de-Lattre-de-Tassigny, 21000 Dijon, France. ·Presse Med · Pubmed #31564552.

ABSTRACT: -- No abstract --

12 Editorial Methotrexate in Giant Cell Arteritis Deserves a Second Chance - A High-dose Methotrexate Trial Is Needed. 2019

Brouwer, Elisabeth / VAN DER Geest, Kornelis S M / Sandovici, Maria. ·Department of Rheumatology and Clinical Immunology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, the Netherlands. e.brouwer@umcg.nl. · Department of Rheumatology and Clinical Immunology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, the Netherlands. ·J Rheumatol · Pubmed #31043498.

ABSTRACT: -- No abstract --

13 Editorial [Management of Giant Cell Arteritis]. 2019

Märker-Hermann, Elisabeth. · ·Dtsch Med Wochenschr · Pubmed #31026865.

ABSTRACT: -- No abstract --

14 Editorial Modulating Adaptive Immunity in Vascular Disease: CD4 to the Fore. 2019

Libby, Peter / Lichtman, Andrew I. ·Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Vascular Research Division, Department of Pathology and the Center of Excellence in Vascular Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ·J Am Coll Cardiol · Pubmed #30975300.

ABSTRACT: -- No abstract --

15 Editorial Picturing Giant Cell Arteritis: Projecting Into the Future. 2019

Tedeschi, Sara K / Aghayev, Ayaz. ·Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts. · Brigham and Women's Hospital, Boston, Massachusetts. ·Arthritis Rheumatol · Pubmed #30825366.

ABSTRACT: -- No abstract --

16 Editorial Monocytes M( MP)aking Way for T-Cell Vascular Infiltration. 2018

Nosalski, Ryszard / Maffia, Pasquale / Guzik, Tomasz J. ·From the Institute of Cardiovascular and Medical Sciences (R.N., P.M., T.J.G.). · College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom; Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland (R.N., T.J.G.). · Centre for Immunobiology, Institute of Infection, Immunity and Inflammation (P.M.). · Department of Pharmacy, University of Naples Federico II, Italy (P.M.). ·Circ Res · Pubmed #30355241.

ABSTRACT: -- No abstract --

17 Editorial Foreword: clinical challenges of diagnosing and managing giant cell arteritis. 2018

Stone, John H. ·Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, USA. ·Rheumatology (Oxford) · Pubmed #29982783.

ABSTRACT: -- No abstract --

18 Editorial Paraneoplastic Large-vessel Vasculitis Associated with Myelodysplastic Syndrome. 2018

Yabe, Hiroki. ·Division of Rheumatology, First Department of Comprehensive Medicine, Jichi Medical University Saitama Medical Center, Japan. ·Intern Med · Pubmed #29780150.

ABSTRACT: -- No abstract --

19 Editorial [Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?] 2018

Samson, M / Bonnotte, B. ·Service de médecine interne et immunologie clinique, CHU Dijon Bourgogne, 2, boulevard Mal-de-Lattre-de-Tassigny, 21000 Dijon, France; Inserm U1098, université Bourgogne-Franche-Comté, FHU Increase, 21000 Dijon, France. ·Rev Med Interne · Pubmed #29217104.

ABSTRACT: -- No abstract --

20 Editorial Fluorodeoxyglucose Positron Emission Tomography for Giant Cell Arteritis. 2017

Blockmans, Daniel. ·Katholieke Universiteit Leuven, General Internal Medicine, Leuven, Belgium. daniel.blockmans@uzleuven.be. ·J Rheumatol · Pubmed #29196543.

ABSTRACT: -- No abstract --

21 Editorial Giant-Cell Arteritis - More Ecstasy, Less Agony. 2017

Hellmann, David B. ·From the Johns Hopkins University School of Medicine, Baltimore. ·N Engl J Med · Pubmed #28745998.

ABSTRACT: -- No abstract --

22 Editorial Editorial: Defining and Refining the Risk of Venous Thromboembolism in Giant Cell Arteritis. 2017

Monach, Paul A. ·Boston University School of Medicine and VA Boston Healthcare System, Boston, Massachusetts. ·Arthritis Rheumatol · Pubmed #28029235.

ABSTRACT: -- No abstract --

23 Editorial Causes of Cardiovascular Ischemic Events in Giant Cell Arteritis. 2016

Richter, Jutta G / Sander, Oliver / Schneider, Matthias. ·Policlinic for Rheumatology and Hiller Research Centre for Rheumatology, Medical Faculty, Heinrich Heine University Düsseldorf; richter@rheumanet.org. · Policlinic for Rheumatology and Hiller Research Centre for Rheumatology, Medical Faculty, Heinrich Heine University Düsseldorf. · Policlinic for Rheumatology and Hiller Research Centre for Rheumatology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. ·J Rheumatol · Pubmed #27909138.

ABSTRACT: -- No abstract --

24 Editorial Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis? 2016

Toussirot, Éric / Régent, Alexis / Devauchelle-Pensec, Valérie / Saraux, Alain / Puéchal, Xavier. ·Clinical Investigation Centre Biotherapy INSERM CIC-1431, University Hospital of Besançon, Besançon, France; Fédération Hospitalo-Universitaire INCREASE, University Hospital of Besançon, Besançon, France; Department of Rheumatology, University Hospital of Besançon, Besançon, France; Department of Therapeutics and UPRES EA 4266 « Agents Pathogènes et Inflammation», University of Bourgogne Franche-Comté, Besançon, France. · Paris-Descartes University, Paris, France; Department of Internal Medicine, Centre de référence maladies auto-immunes et systémiques rares, Hôpital Cochin, AP-HP, Paris, France. · Department of Rheumatology , University Hospital of Brest , Brest , France. · Department of Internal Medicine , Centre de référence maladies auto-immunes et systémiques rares, Hôpital Cochin, AP-HP , Paris , France. ·RMD Open · Pubmed #27738520.

ABSTRACT: -- No abstract --

25 Editorial Large vessel vasculitis: the search for response biomarkers. 2016

Tombetti, Enrico / Mason, Justin. ·a Unit of Internal Medicine and Clinical Immunology , San Raffele Scientific Institute , Milano , Italy. · b Rheumatology and Vascular Science, Imperial College Faculty of Medicine , London , UK. ·Expert Rev Clin Immunol · Pubmed #27551980.

ABSTRACT: -- No abstract --

Next